

Table 4.25

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	304,428	99.4%	241,361	99.5%	33,627	99.3%	25,184	99.3%	1,296	99.2%	33,042	99.2%
Epidermoid carcinoma ^d (8051-8131)	153	0.1%	123	0.1%	21	0.1%	-	-	-	-	-	-
Adenocarcinoma ^e	298,577	97.5%	236,978	97.7%	32,637	96.3%	24,808	97.8%	1,268	97.1%	32,356	97.2%
Adenocarcinoma, NOS (8140)	2,194	0.7%	1,709	0.7%	291	0.9%	150	0.6%	-	-	245	0.7%
Infiltrating duct carcinoma (8500)	225,092	73.5%	176,510	72.7%	25,569	75.5%	19,807	78.1%	1,010	77.3%	24,835	74.6%
Lobular carcinoma, NOS (8520)	28,594	9.3%	24,243	10.0%	2,498	7.4%	1,482	5.8%	103	7.9%	2,584	7.8%
Inflammatory adenocarcinoma (8530)	855	0.3%	679	0.3%	112	0.3%	53	0.2%	-	-	144	0.4%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	27,845	9.1%	22,988	9.5%	2,500	7.4%	2,012	7.9%	86	6.6%	3,140	9.4%
Mucinous adenocarcinoma (8480,8482)	5,795	1.9%	4,427	1.8%	691	2.0%	605	2.4%	22	1.7%	580	1.7%
Mucin-producing adenocarcinoma (8481)	64	0.0%	47	0.0%	-	-	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	1,660	0.5%	1,480	0.6%	94	0.3%	78	0.3%	-	-	135	0.4%
Papillary adenocarcinoma (8050,8260,8503,8504)	1,923	0.6%	1,355	0.6%	316	0.9%	221	0.9%	-	-	197	0.6%
Paget disease (8540-8543)	1,080	0.4%	856	0.4%	108	0.3%	105	0.4%	-	-	122	0.4%
Other adenocarcinomas ^f	3,475	1.1%	2,684	1.1%	447	1.3%	291	1.1%	-	-	365	1.1%
Other specific carcinomas ^g	2,484	0.8%	1,832	0.8%	454	1.3%	170	0.7%	-	-	331	1.0%
Medullary adenocarcinoma (8510-8513)	719	0.2%	489	0.2%	175	0.5%	49	0.2%	-	-	153	0.5%
Other ^h	1,765	0.6%	1,343	0.6%	279	0.8%	121	0.5%	-	-	178	0.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	3,214	1.0%	2,428	1.0%	515	1.5%	198	0.8%	16	1.2%	342	1.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^h Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.25 - continued

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	334	0.1%	252	0.1%	52	0.2%	24	0.1%	-	-	38	0.1%
Hemangiosarcomas (9120-9126,9170)	169	0.1%	138	0.1%	18	0.1%	-	-	-	-	-	-
Other sarcomas ^d	165	0.1%	114	0.0%	34	0.1%	-	-	-	-	23	0.1%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	728	0.2%	519	0.2%	91	0.3%	104	0.4%	-	-	130	0.4%
Phyllodes tumor, malignant (9020)	620	0.2%	439	0.2%	70	0.2%	97	0.4%	-	-	111	0.3%
Other ^e	108	0.0%	80	0.0%	21	0.1%	-	-	-	-	19	0.1%
Unspecified (8000-8005)	708	0.2%	524	0.2%	105	0.3%	54	0.2%	-	-	94	0.3%
Total ^f	306,198	100.0%	242,656	100.0%	33,875	100.0%	25,366	100.0%	1,306	100.0%	33,304	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^e Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^f Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	76,695	99.9%	58,604	99.9%	8,733	99.9%	7,985	99.9%	290	100.0%	7,939	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^e	65,234	85.0%	49,267	84.0%	7,664	87.6%	7,232	90.5%	253	87.2%	6,798	85.5%
Cribriform carcinoma <i>in situ</i> (8201/2)	6,769	8.8%	5,030	8.6%	814	9.3%	816	10.2%	18	6.2%	696	8.8%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	5,417	7.1%	4,226	7.2%	541	6.2%	578	7.2%	20	6.9%	481	6.1%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	21,448	27.9%	16,542	28.2%	2,436	27.9%	2,050	25.7%	97	33.4%	2,204	27.7%
Comedocarcinoma <i>in situ</i> (8501/2)	6,419	8.4%	4,849	8.3%	706	8.1%	773	9.7%	35	12.1%	629	7.9%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,148	1.5%	780	1.3%	204	2.3%	141	1.8%	-	-	120	1.5%
Noninfiltrating intracystic carcinoma(8504/2)	249	0.3%	160	0.3%	36	0.4%	52	0.7%	-	-	29	0.4%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,205	1.6%	950	1.6%	153	1.7%	86	1.1%	-	-	138	1.7%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	22,396	29.2%	16,602	28.3%	2,764	31.6%	2,692	33.7%	76	26.2%	2,486	31.3%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	8,904	11.6%	7,339	12.5%	783	9.0%	515	6.4%	32	11.0%	905	11.4%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	8,886	11.6%	7,327	12.5%	778	8.9%	515	6.4%	31	10.7%	904	11.4%
Lobular CIS ^f with other CIS ^f (8524/2)	18	0.0%	-	-	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,043	2.7%	1,626	2.8%	222	2.5%	169	2.1%	-	-	180	2.3%
Other adenocarcinomas ^g	506	0.7%	368	0.6%	63	0.7%	66	0.8%	-	-	56	0.7%
Other <i>in situ</i> histologies ^h	85	0.1%	62	0.1%	-	-	-	-	-	-	-	-
Total	76,780	100.0%	58,666	100.0%	8,746	100.0%	7,990	100.0%	290	100.0%	7,948	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^g CIS = Carcinoma *in situ*.

^h Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

ⁱ Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	16,125	98.0%	11,963	98.2%	2,240	96.9%	1,523	98.4%	129	99.2%	3,582	98.2%
Epidermoid carcinoma ^d (8050-8131)	10,730	65.2%	7,735	63.5%	1,738	75.2%	989	63.9%	84	64.6%	2,445	67.0%
Squamous cell carcinoma (8070)	7,551	45.9%	5,403	44.3%	1,266	54.8%	688	44.4%	64	49.2%	1,604	44.0%
Squamous cell, keratinizing (8071)	1,124	6.8%	786	6.5%	204	8.8%	108	7.0%	-	-	289	7.9%
Squamous cell, non-keratinizing (8072)	1,443	8.8%	1,085	8.9%	184	8.0%	144	9.3%	-	-	398	10.9%
Squamous cell, Microinvasive (8076)	351	2.1%	272	2.2%	41	1.8%	26	1.7%	-	-	85	2.3%
Other (8050-8069, 8073-8075,8077-8131)	261	1.6%	189	1.6%	43	1.9%	23	1.5%	-	-	69	1.9%
Adenocarcinoma ^e	4,713	28.6%	3,740	30.7%	393	17.0%	467	30.2%	42	32.3%	996	27.3%
Adenocarcinoma, NOS (8140)	2,479	15.1%	1,972	16.2%	208	9.0%	242	15.6%	19	14.6%	532	14.6%
Adenosquamous (8560,8570)	545	3.3%	407	3.3%	61	2.6%	70	4.5%	-	-	126	3.5%
Other adenocarcinomas ^f	1,689	10.3%	1,361	11.2%	124	5.4%	155	10.0%	18	13.8%	338	9.3%
Other specific carcinomas ^g	274	1.7%	198	1.6%	45	1.9%	28	1.8%	-	-	49	1.3%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	408	2.5%	290	2.4%	64	2.8%	39	2.5%	-	-	92	2.5%
Sarcoma ^h	59	0.4%	40	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	167	1.0%	107	0.9%	34	1.5%	19	1.2%	-	-	28	0.8%
Unspecified (8000-8005)	107	0.7%	76	0.6%	22	1.0%	-	-	-	-	22	0.6%
Total	16,458	100.0%	12,186	100.0%	2,311	100.0%	1,548	100.0%	130	100.0%	3,647	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	178,732	99.4%	138,841	99.5%	21,843	99.4%	14,829	99.4%	1,056	99.5%	19,622	99.4%
Epidermoid carcinoma ^d (8051-8131)	1,143	0.6%	979	0.7%	119	0.5%	21	0.1%	-	-	99	0.5%
Squamous cell carcinoma (8070-8078,8083-8084)	1,100	0.6%	947	0.7%	114	0.5%	20	0.1%	-	-	96	0.5%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	166,401	92.6%	130,503	93.5%	19,644	89.4%	13,717	91.9%	967	91.1%	18,191	92.1%
Adenocarcinoma, NOS (8140)	114,519	63.7%	89,598	64.2%	13,534	61.6%	9,858	66.0%	701	66.1%	12,632	64.0%
Adenocarcinoma in adenomatous polyp (8210)	15,339	8.5%	11,877	8.5%	1,752	8.0%	1,305	8.7%	107	10.1%	1,397	7.1%
Adenocarcinoma in villous adenoma (8261)	3,614	2.0%	2,895	2.1%	411	1.9%	261	1.7%	-	-	499	2.5%
Mucinous adenocarcinoma (8470-8473,8480,8482)	11,462	6.4%	9,412	6.7%	1,194	5.4%	743	5.0%	51	4.8%	1,376	7.0%
Mucin-producing adenocarcinoma (8481)	1,337	0.7%	1,048	0.8%	183	0.8%	96	0.6%	-	-	142	0.7%
Signet ring adenocarcinoma (8490)	2,061	1.1%	1,682	1.2%	214	1.0%	145	1.0%	-	-	236	1.2%
Other adenocarcinomas ^e	18,069	10.1%	13,991	10.0%	2,356	10.7%	1,309	8.8%	84	7.9%	1,909	9.7%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	9,757	5.4%	6,240	4.5%	1,908	8.7%	995	6.7%	62	5.8%	1,176	6.0%
Neuroendocrine carcinoid (8240-8245)	7,135	4.0%	4,317	3.1%	1,511	6.9%	792	5.3%	54	5.1%	918	4.6%
Other ^f	2,622	1.5%	1,923	1.4%	397	1.8%	203	1.4%	-	-	258	1.3%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,431	0.8%	1,119	0.8%	172	0.8%	96	0.6%	23	2.2%	156	0.8%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	121	0.1%	95	0.1%	16	0.1%	-	-	-	-	20	0.1%
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	282	0.2%	187	0.1%	47	0.2%	46	0.3%	-	-	34	0.2%
Unspecified (8000-8005)	614	0.3%	453	0.3%	65	0.3%	43	0.3%	-	-	72	0.4%
Total ^d	179,749	100.0%	139,576	100.0%	21,971	100.0%	14,926	100.0%	1,061	100.0%	19,748	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	18,880	99.1%	15,900	99.1%	1,916	99.3%	853	99.3%	85	100.0%	1,458	98.8%
Epidermoid carcinoma ^d (8051-8131)	6,211	32.6%	4,033	25.1%	1,520	78.8%	588	68.5%	32	37.6%	538	36.5%
Squamous cell carcinoma (8070-8078, 8083-8084)	6,193	32.5%	4,025	25.1%	1,511	78.3%	587	68.3%	32	37.6%	538	36.5%
Adenocarcinoma ^e	11,875	62.4%	11,185	69.7%	333	17.3%	230	26.8%	50	58.8%	850	57.6%
Other specific carcinomas ^f	289	1.5%	240	1.5%	25	1.3%	20	2.3%	-	-	25	1.7%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	505	2.7%	442	2.8%	38	2.0%	-	-	-	-	45	3.1%
Other specific types ^g	56	0.3%	46	0.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	108	0.6%	95	0.6%	-	-	-	-	-	-	-	-
Total	19,044	100.0%	16,041	100.0%	1,930	100.0%	859	100.0%	85	100.0%	1,475	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma is defined as histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas is defined as histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^h Other specific types includes sarcomas and other soft tissue tumors.

ⁱ Other specific types is defined as histologies 8680-8713, 8720-8790, 8800-8921, 8930-8936, 8950-9030, 9040-9044, 9060-9110, 9120-9136, 9150-9252, 9260-9365, 9370-9373, 9380-9539, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	23,490	97.2%	16,767	97.1%	3,004	97.4%	3,333	97.5%	206	97.2%	4,106	95.9%
Hepatocellular carcinoma ^d (8170-8175)	17,557	72.7%	12,108	70.1%	2,470	80.1%	2,661	77.9%	166	78.3%	3,189	74.5%
Cholangiocarcinoma (8032-8033,8070-8071, 8140-8141,8160,8260, 8480-8481,8490,8560)	4,987	20.6%	3,961	22.9%	408	13.2%	560	16.4%	33	15.6%	764	17.8%
Other carcinoma ^e	944	3.9%	697	4.0%	126	4.1%	111	3.2%	-	-	153	3.6%
Other specific carcinoma ^f	610	2.5%	446	2.6%	76	2.5%	81	2.4%	-	-	96	2.2%
Unspecified, Carcinoma, NOS (8010,8020-8022,8031, 8046,8050)	334	1.4%	251	1.5%	50	1.6%	30	0.9%	-	-	57	1.3%
Hepatoblastoma (8970)	243	1.0%	177	1.0%	27	0.9%	30	0.9%	-	-	78	1.8%
Sarcoma ^g	199	0.8%	146	0.8%	21	0.7%	30	0.9%	-	-	36	0.8%
Hemangiosarcoma (9120)	88	0.4%	61	0.4%	-	-	17	0.5%	-	-	-	-
Other sarcomas ^h	111	0.5%	85	0.5%	-	-	-	-	-	-	22	0.5%
Other specific types (8720,8980,8991,9061, 9064,9070-9071,9080, 9100)	44	0.2%	34	0.2%	-	-	-	-	-	-	16	0.4%
Unspecified (8000-8004)	183	0.8%	137	0.8%	22	0.7%	21	0.6%	-	-	47	1.1%
Total ^d	24,165	100.0%	17,264	100.0%	3,083	100.0%	3,417	100.0%	212	100.0%	4,283	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma arising from liver parenchyma are referred to as hepatocellular carcinoma.

^f Other carcinoma include histologies 8010, 8012-8013, 8020-8022, 8031, 8035, 8041-8042, 8046, 8050, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^g Other specific carcinoma include histologies 8012-8013, 8035, 8041-8042, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^h Sarcoma includes histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9120, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

ⁱ Other sarcomas include histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.28

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Both Sexes by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	49.2	226,536	99.7%	185,073	99.7%	25,714	99.8%	14,106	99.8%	768	99.5%	13,329	99.5%
Small cell (8002,8041-8045)	6.3	29,654	13.1%	25,769	13.9%	2,654	10.3%	1,023	7.2%	125	16.2%	1,395	10.4%
Non-small cell	41.5	190,304	83.8%	154,056	83.0%	22,207	86.2%	12,658	89.5%	620	80.3%	11,446	85.4%
Squamous and transitional cell ^d	11.6	52,719	23.2%	43,884	23.6%	6,216	24.1%	2,199	15.6%	231	29.9%	2,620	19.6%
Adenocarcinoma ^e	23.0	105,863	46.6%	84,119	45.3%	12,164	47.2%	8,864	62.7%	279	36.1%	6,712	50.1%
Large cell ^f	0.8	3,725	1.6%	3,057	1.6%	495	1.9%	155	1.1%	-	-	174	1.3%
Non-small cell carcinoma ^g	3.5	16,205	7.1%	12,914	7.0%	2,220	8.6%	928	6.6%	72	9.3%	1,029	7.7%
Other specified carcinomas ^h	2.6	11,792	5.2%	10,082	5.4%	1,112	4.3%	512	3.6%	31	4.0%	911	6.8%
Carcinoma, NOS ⁱ	1.4	6,578	2.9%	5,248	2.8%	853	3.3%	425	3.0%	23	3.0%	488	3.6%
Sarcoma ^j	0.1	417	0.2%	344	0.2%	42	0.2%	24	0.2%	-	-	51	0.4%
Other specified types ^k	0.0	200	0.1%	169	0.1%	21	0.1%	-	-	-	-	-	-
Total	49.4	227,153	100.0%	185,586	100.0%	25,777	100.0%	14,140	100.0%	772	100.0%	13,395	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Males by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	57.7	118,770	99.7%	95,840	99.7%	14,190	99.7%	7,874	99.8%	413	99.5%	6,966	99.4%
Small cell (8002,8041-8045)	7.0	14,762	12.4%	12,629	13.1%	1,345	9.5%	687	8.7%	63	15.2%	721	10.3%
Non-small cell	48.9	100,280	84.2%	80,296	83.5%	12,323	86.6%	6,927	87.8%	337	81.2%	5,956	85.0%
Squamous and transitional cell ^d	16.2	32,888	27.6%	27,126	28.2%	3,914	27.5%	1,590	20.1%	134	32.3%	1,638	23.4%
Adenocarcinoma ^e	24.6	50,719	42.6%	39,761	41.4%	6,248	43.9%	4,366	55.3%	141	34.0%	3,225	46.0%
Large cell ^f	1.0	2,087	1.8%	1,674	1.7%	303	2.1%	99	1.3%	-	-	104	1.5%
Non-small cell carcinoma ^g	4.4	9,198	7.7%	7,213	7.5%	1,312	9.2%	595	7.5%	42	10.1%	583	8.3%
Other specified carcinomas ^h	2.6	5,388	4.5%	4,522	4.7%	546	3.8%	277	3.5%	18	4.3%	406	5.8%
Carcinoma, NOS ⁱ	1.9	3,728	3.1%	2,915	3.0%	522	3.7%	260	3.3%	-	-	289	4.1%
Sarcoma ^j	0.1	251	0.2%	210	0.2%	27	0.2%	-	-	-	-	32	0.5%
Other specified types ^k	0.1	121	0.1%	102	0.1%	-	-	-	-	-	-	-	-
Total	57.9	119,142	100.0%	96,152	100.0%	14,230	100.0%	7,891	100.0%	415	100.0%	7,007	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Females by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	42.8	107,766	99.8%	89,233	99.8%	11,524	99.8%	6,232	99.7%	355	99.4%	6,363	99.6%
Small cell (8002,8041-8045)	5.9	14,892	13.8%	13,140	14.7%	1,309	11.3%	336	5.4%	62	17.4%	674	10.6%
Non-small cell	35.8	90,024	83.3%	73,760	82.5%	9,884	85.6%	5,731	91.7%	283	79.3%	5,490	85.9%
Squamous and transitional cell ^d	8.0	19,831	18.4%	16,758	18.7%	2,302	19.9%	609	9.7%	97	27.2%	982	15.4%
Adenocarcinoma ^e	21.9	55,144	51.1%	44,358	49.6%	5,916	51.2%	4,498	72.0%	138	38.7%	3,487	54.6%
Large cell ^f	0.7	1,638	1.5%	1,383	1.5%	192	1.7%	56	0.9%	-	-	70	1.1%
Non-small cell carcinoma ^g	2.8	7,007	6.5%	5,701	6.4%	908	7.9%	333	5.3%	30	8.4%	446	7.0%
Other specified carcinomas ^h	2.6	6,404	5.9%	5,560	6.2%	566	4.9%	235	3.8%	-	-	505	7.9%
Carcinoma, NOS ⁱ	1.1	2,850	2.6%	2,333	2.6%	331	2.9%	165	2.6%	-	-	199	3.1%
Sarcoma ^j	0.1	166	0.2%	134	0.1%	-	-	-	-	-	-	19	0.3%
Other specified types ^k	0.0	79	0.1%	67	0.1%	-	-	-	-	-	-	-	-
Total	42.9	108,011	100.0%	89,434	100.0%	11,547	100.0%	6,249	100.0%	357	100.0%	6,388	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	44,599	85.2%	2,931	94.4%	15,420	97.5%	1,239	21.7%	2,383	95.8%
Squamous cell carcinoma (8070-8078,8083-8084)	43,561	83.2%	2,814	90.6%	15,151	95.8%	1,186	20.8%	2,357	94.8%
Adenocarcinoma ^c	5,098	9.7%	122	3.9%	203	1.3%	3,561	62.4%	75	3.0%
Other specific carcinomas ^d	458	0.9%	-	-	38	0.2%	266	4.7%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,563	3.0%	-	-	82	0.5%	431	7.5%	-	-
Sarcoma and soft tissue ^e	169	0.3%	-	-	22	0.1%	36	0.6%	-	-
Other specific types ^f	284	0.5%	24	0.8%	-	-	119	2.1%	-	-
Unspecified (8000-8005)	203	0.4%	-	-	43	0.3%	58	1.0%	-	-
Total	52,375	100.0%	3,106	100.0%	15,821	100.0%	5,710	100.0%	2,487	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	5,653	82.3%	1,804	64.6%	11,523	98.0%	2,698	97.6%	948	89.1%
Squamous cell carcinoma (8070-8078,8083-8084)	5,385	78.4%	1,662	59.5%	11,387	96.8%	2,683	97.1%	936	88.0%
Adenocarcinoma ^c	972	14.2%	72	2.6%	62	0.5%	-	-	19	1.8%
Other specific carcinomas ^d	30	0.4%	42	1.5%	40	0.3%	-	-	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	61	0.9%	808	29.0%	92	0.8%	24	0.9%	46	4.3%
Sarcoma and soft tissue ^e	35	0.5%	32	1.1%	-	-	-	-	-	-
Other specific types ^f	97	1.4%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	20	0.3%	18	0.6%	26	0.2%	-	-	27	2.5%
Total	6,869	100.0%	2,791	100.0%	11,763	100.0%	2,764	100.0%	1,064	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,756	91.6%	20,308	92.2%	2,063	87.5%	2,109	91.1%	118	86.1%	3,178	87.5%
Epidermoid carcinoma ^d (8051-8131)	172	0.6%	130	0.6%	17	0.7%	25	1.1%	-	-	32	0.9%
Adenocarcinoma ^e	22,797	84.3%	18,817	85.4%	1,793	76.1%	1,937	83.7%	109	79.6%	2,881	79.3%
Adenocarcinoma, NOS (8140)	2,891	10.7%	2,353	10.7%	350	14.8%	159	6.9%	-	-	353	9.7%
Papillary adenocarcinoma, NOS (8050,8260)	266	1.0%	215	1.0%	28	1.2%	17	0.7%	-	-	33	0.9%
Clear cell adenocarcinoma (8310,9110)	1,478	5.5%	1,108	5.0%	76	3.2%	275	11.9%	-	-	166	4.6%
Endometrioid carcinoma (8380-8383,8570)	2,668	9.9%	2,169	9.8%	145	6.2%	324	14.0%	-	-	415	11.4%
Cystadenocarcinoma, NOS (8440,8450)	61	0.2%	48	0.2%	-	-	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	7,751	28.7%	6,517	29.6%	596	25.3%	550	23.8%	41	29.9%	858	23.6%
Papillary serous cystadenocarcinoma (8460-8462)	4,807	17.8%	4,068	18.5%	391	16.6%	302	13.0%	21	15.3%	612	16.9%
Mucinous cystadenocarcinoma (8470-8473)	328	1.2%	257	1.2%	21	0.9%	46	2.0%	-	-	45	1.2%
Mucinous adenocarcinoma (8480,8482)	1,082	4.0%	861	3.9%	88	3.7%	118	5.1%	-	-	161	4.4%
Mucin-producing adenocarcinoma(8481)	26	0.1%	19	0.1%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,439	5.3%	1,202	5.5%	87	3.7%	138	6.0%	-	-	224	6.2%
Other specific carcinomas ^g	670	2.5%	464	2.1%	143	6.1%	50	2.2%	-	-	111	3.1%
Stromal cell tumor (8620-8631,8650)	487	1.8%	324	1.5%	119	5.0%	33	1.4%	-	-	83	2.3%
Other ^h	183	0.7%	140	0.6%	24	1.0%	17	0.7%	-	-	28	0.8%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,117	4.1%	897	4.1%	110	4.7%	97	4.2%	-	-	154	4.2%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	84	0.3%	60	0.3%	16	0.7%	-	-	-	-	21	0.6%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,890	7.0%	1,439	6.5%	231	9.8%	172	7.4%	-	-	392	10.8%
Mullerian mixed tumor (8950-8951,8980)	892	3.3%	739	3.4%	85	3.6%	53	2.3%	-	-	109	3.0%
Teratoma, malignant (9080-9085,9102)	404	1.5%	264	1.2%	67	2.8%	54	2.3%	-	-	145	4.0%
Other	594	2.2%	436	2.0%	79	3.4%	65	2.8%	-	-	138	3.8%
Unspecified (8000-8005)	301	1.1%	218	1.0%	47	2.0%	28	1.2%	-	-	40	1.1%
Total ^d	27,031	100.0%	22,025	100.0%	2,357	100.0%	2,315	100.0%	137	100.0%	3,631	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	46,646	98.2%	37,069	98.2%	5,717	98.2%	3,467	98.0%	184	96.3%	4,891	97.7%
Epidermoid carcinoma ^d (8051-8131)	131	0.3%	92	0.2%	25	0.4%	-	-	-	-	-	-
Adenocarcinoma ^e	40,403	85.0%	32,212	85.3%	4,901	84.2%	2,962	83.7%	163	85.3%	4,200	83.9%
Adenocarcinoma, NOS (8140)	32,784	69.0%	26,148	69.3%	4,061	69.8%	2,308	65.3%	134	70.2%	3,360	67.1%
Papillary adenocarcinoma, NOS (8260)	28	0.1%	20	0.1%	-	-	-	-	-	-	-	-
Mucinous adenocarcinoma (8480,8482)	1,097	2.3%	881	2.3%	101	1.7%	99	2.8%	-	-	130	2.6%
Mucin-producing adenocarcinoma (8481)	343	0.7%	285	0.8%	38	0.7%	20	0.6%	-	-	33	0.7%
Infiltrating duct carcinoma (8500-8503,8507,8514)	4,909	10.3%	3,888	10.3%	550	9.5%	440	12.4%	17	8.9%	505	10.1%
Other adenocarcinoma ^f	1,242	2.6%	990	2.6%	147	2.5%	91	2.6%	-	-	168	3.4%
Other specific carcinomas ^g	4,162	8.8%	3,275	8.7%	495	8.5%	343	9.7%	-	-	448	9.0%
Islet cell carcinoma (8150-8155)	289	0.6%	240	0.6%	31	0.5%	-	-	-	-	29	0.6%
Other carcinomas ^h	3,873	8.2%	3,035	8.0%	464	8.0%	328	9.3%	-	-	419	8.4%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	1,951	4.1%	1,491	3.9%	296	5.1%	149	4.2%	-	-	232	4.6%
Sarcoma and other soft tissue tumors ⁱ	44	0.1%	34	0.1%	-	-	-	-	-	-	-	-
Other specific types ^j	48	0.1%	40	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	771	1.6%	604	1.6%	92	1.6%	63	1.8%	-	-	98	2.0%
Total	47,511	100.0%	37,748	100.0%	5,819	100.0%	3,537	100.0%	191	100.0%	5,004	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

^j Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	29,990	92.1%	21,430	92.7%	3,857	87.6%	4,165	93.1%	251	96.9%	5,665	95.0%
Epidermoid carcinoma ^d (8051-8131)	298	0.9%	209	0.9%	54	1.2%	30	0.7%	-	-	32	0.5%
Squamous cell carcinoma (8070-8078,8083-8084)	289	0.9%	202	0.9%	54	1.2%	28	0.6%	-	-	28	0.5%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	26,666	81.9%	18,927	81.9%	3,376	76.6%	3,930	87.9%	222	85.7%	5,027	84.3%
Adenocarcinoma, NOS (8140)	15,278	46.9%	11,304	48.9%	1,872	42.5%	1,878	42.0%	121	46.7%	2,359	39.6%
Adenocarcinoma, intestinal type (8144)	2,774	8.5%	1,649	7.1%	447	10.1%	629	14.1%	28	10.8%	558	9.4%
Carcinoma, diffuse type (8145)	1,332	4.1%	824	3.6%	155	3.5%	320	7.2%	17	6.6%	349	5.9%
Linitus plastica (8142)	166	0.5%	125	0.5%	-	-	25	0.6%	-	-	43	0.7%
Mucinous adenocarcinoma (8470-8473,8480,8482)	415	1.3%	291	1.3%	59	1.3%	56	1.3%	-	-	69	1.2%
Mucin-producing adenocarcinoma (8481)	105	0.3%	78	0.3%	19	0.4%	-	-	-	-	22	0.4%
Signet ring adenocarcinoma (8490)	5,318	16.3%	3,773	16.3%	639	14.5%	810	18.1%	46	17.8%	1,374	23.0%
Other adenocarcinomas ^e	1,278	3.9%	883	3.8%	171	3.9%	204	4.6%	-	-	253	4.2%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	2,371	7.3%	1,837	7.9%	329	7.5%	122	2.7%	19	7.3%	506	8.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	655	2.0%	457	2.0%	98	2.2%	83	1.9%	-	-	100	1.7%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22 - continued

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	80	0.2%	64	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	2,316	7.1%	1,488	6.4%	515	11.7%	285	6.4%	-	-	240	4.0%
Unspecified (8000-8005)	174	0.5%	126	0.5%	22	0.5%	19	0.4%	-	-	46	0.8%
Total ^d	32,560	100.0%	23,108	100.0%	4,405	100.0%	4,473	100.0%	259	100.0%	5,962	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	63,229	99.7%	50,846	99.7%	4,408	99.6%	6,519	99.8%	300	100.0%	10,006	99.7%
Epidermoid carcinoma ^d (8051-8131)	67	0.1%	55	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	61,228	96.5%	49,226	96.5%	4,235	95.7%	6,337	97.0%	294	98.0%	9,705	96.7%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	56,724	89.4%	45,722	89.7%	3,721	84.1%	5,959	91.2%	266	88.7%	9,104	90.7%
Follicular carcinoma (8330-8332,8335)	2,939	4.6%	2,248	4.4%	363	8.2%	260	4.0%	-	-	420	4.2%
Oxyphilic (8290)	1,242	2.0%	1,010	2.0%	116	2.6%	81	1.2%	-	-	142	1.4%
Other specific carcinomas ^f	1,096	1.7%	922	1.8%	88	2.0%	74	1.1%	-	-	172	1.7%
Medullary carcinoma (8510)	1,056	1.7%	888	1.7%	85	1.9%	71	1.1%	-	-	167	1.7%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	838	1.3%	643	1.3%	82	1.9%	99	1.5%	-	-	121	1.2%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	514	0.8%	407	0.8%	43	1.0%	60	0.9%	-	-	72	0.7%
Sarcoma and other soft tissue tumors ^g	18	0.0%	-	-	-	-	-	-	-	-	-	-
Other specific types ^h	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	171	0.3%	125	0.2%	-	-	16	0.2%	-	-	26	0.3%
Total	63,426	100.0%	50,993	100.0%	4,426	100.0%	6,535	100.0%	300	100.0%	10,038	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

^h Sarcoma and other soft tissue tumors include histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.